BSEBoard Meeting21 Oct 2026 · 21 Oct 2026, 05:09 pm
Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.
Alivus Life Sciences Ltd · 543322
✦ AI SummaryResults
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alivus Life Sciences Ltd - 543322 - Board Meeting Intimation for Inter-Alia, Considering And Approving Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2026.
Attachments (1)
📄pdf
Download →
e3474007-9b43-4679-a8d6-f76d50c22a0d.pdf
View document text
October 21, 2026
To, To,
Dy. General Manager The Manager – Listing,
Department of Corporate Services, National Stock Exchange of India Ltd.,
BSE Ltd., Plot No. C/1, G Block,
P. J. Towers, Dalal Street, Bandra Kurla Complex,
Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS
Dear Sirs,
Sub: Board Meeting
We have to inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India
(Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors
will be held on Thursday, October 29, 2026 inter alia, to consider and approve the Unaudited Financial
Results of the Company for the quarter and half year ended 30th September, 2026.
Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI
(Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ‘designated persons’
regarding the closure of the Trading Window from October 1, 2026 to October 31, 2026 (both days
inclusive) for the purpose of approval of Unaudited Financial Results for quarter and half year ended
30th September, 2026.
The above is for your information.
Thanking you.
Yours faithfully,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)
Rudalf Corriea
Company Secretary & Compliance Officer
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited )
Corporate Office: R egistered Office:
Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, P lot No 170-172, Chandramouli Industrial Estate
4th Floor, Mahakali Caves Road, Andheri ( E), Mumba–i 400093 M ohol Bazarpeth, Solapur 413 213, India
T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com